![Earle Burgess: Another interesting new drug in development for metastatic castrate resistant prostate cancer](https://oncodaily.com/pub/uploads/2023/08/Earle-Burgess-1-e1706723177147-1280x1028.jpg)
Photo from Earle Burgess/LinkedIn
Jul 25, 2024, 08:49
Earle Burgess: Another interesting new drug in development for metastatic castrate resistant prostate cancer
Earle Burgess, Genitourinary Medical Oncologist at Atrium Health, Levine Cancer Institute, shared on LinkedIn:
”ARV-766: another interesting new drug in development for metastatic castrate resistant prostate cancer (mCRPC) with promising early phase data presented at ASCO24.
ARV-766 is an AR ‘PROTAC,’ a molecule that enhances degradation of the androgen receptor (AR) inside of prostate cancer cells.
20-25% of patients with mCRPC have tumor mutations in the AR ligand binding domain (LBD).
In a small cohort of heavily pretreated mCRPC patients whose tumors had mutations in the AR LBD, ARV-766 led to a 50% decrease in PSA levels in 43% of patients.
Impressive preliminary data for this patient population.”
Source: Earle Burgess/LinkedIn
Jul 25, 2024, 08:00